BioPorto Investor Relations Material
Latest events
Q1 2025
BioPorto
Q1 2025
8 May, 2025
Q4 2024
20 Mar, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from BioPorto
Access all reports
BioPorto A/S is a global biotech company that specializes in the development and manufacturing of in-vitro diagnostic tests and antibodies for both research and clinical applications. The company's diagnostics products are primarily based on a patented proprietary technology platform called MoAb®. The Company's products are used in research, including preclinical studies and clinical trials, as well as in diagnosis procedures to detect infectious diseases, cancer, autoimmune disorders and other diseases. BioPorto A/S is based in Hellerup, Denmark.
Key slides for BioPorto
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
BIOPOR
Country
🇩🇰 Denmark